Identification and Semi -Quantification of ER/PR Proteins Expression
NCT ID: NCT02654431
Last Updated: 2016-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
350 participants
OBSERVATIONAL
2013-05-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying ER/PR IHC stained samples.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue
NCT02654444
Identification and Semi-Quantification of Ki-67 Protein Expression Status
NCT02654457
Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics
NCT00656604
Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections
NCT01066507
Histolog Comparison to Standard Histology
NCT04857229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast Cancer patients
Breast cancer patients
Breast Cancer patient
Samples
Cancer patients
Samples
women with breast cancer
women with breast cancer
Breast Cancer patient
Samples
Cancer patients
Samples
Cancer patients
Cancer patients
Breast Cancer patient
Samples
Cancer patients
Samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Breast Cancer patient
Samples
Cancer patients
Samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Applied Spectral Imaging Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheila Dobin
Role: STUDY_CHAIR
Section Chief, Cytogenetics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scott & White Hospital,,
Temple, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASI-ER/PR-IHC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.